Agreement includes research collaboration to generate follow-up TRI compounds
WILMINGTON, Del., Feb. 9 /PRNewswire-FirstCall/ -- AstraZeneca, Mayo Clinic, and Virginia Tech Intellectual Properties Inc. today announced that AstraZeneca has licensed a portfolio of preclinical Triple Reuptake Inhibitor (TRI) compounds for depression. Researchers at
Current classes of antidepressant therapies such as selective serotonin (SSRI) and dual serotonin/norepinephrine (SNRI) reuptake inhibitors are proven treatments for depression and anxiety. However, they only address the imbalances of one or two of the neurotransmitters in the brain.
Paul R. Carlier, Professor of Organic and Medicinal Chemistry at
Elliott Richelson, M.D., Mayo Clinic, co-inventor of the technology adds, "Through our clinical practice, we recognize the need for improved therapies to treat individuals suffering from depression or anxiety. The additional dopamine action of our TRI compounds has the potential to deliver a superior antidepressant in terms of greater efficacy and an improved side effect profile. By collaborating with AstraZeneca, a company with a strong history of developing new medicines, we have the opportunity to both advance and expand upon these scientific discoveries to address better the needs of patients worldwide."
Christer Kohler, Vice President for AstraZeneca's Global Discovery Research Area focused on Central Nervous System & Pain, says "Besides enabling us to harness the combined power of two outstanding, world-class institutions, this agreement also establishes a strong footing for AstraZeneca in the strategically important TRI research area. We continue to build alliances and collaborations within the scientific community and this deal is another example of our strong commitment and ability to leverage innovation with the aim of making a meaningful difference in patients' lives."
February 9, 2009
NOTES TO EDITORS
AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.
For more information visit http://www.astrazeneca-us.com./
About Mayo Clinic's Office of Intellectual Property
Mayo Clinic has one of the most highly evolved intellectual property and technology commercialization efforts in academic medicine, with a 20-year history of supporting Mayo's mission. The Office of Intellectual Property at Mayo Clinic, serves as a bridge between discoveries and the marketplace. Our staff works closely with Mayo physicians and scientists to evaluate and develop inventions, ideas and discoveries that have the potential to transform healthcare and generate income to support Mayo patient care, education and research. At Mayo Clinic, we work with inventors and industry to determine the right fit for each innovation, whether a sponsored research agreement, licensing agreement, technology-based venture, start-up company or entirely new business model. Mayo Clinic's Office of Intellectual Property has filed more than 2,800 patent applications resulting in more than 500 active licensing agreements with companies in the biomedical and manufacturing industries.
For more information, visit www.mayoclinic.org
Founded in 1872 as a land-grant college, Virginia Tech is the most comprehensive university in the Commonwealth of Virginia and is among the top research universities in the nation. The university's nine colleges are dedicated to quality, innovation, and results through teaching, research, and outreach activities. At its main campus in Blacksburg and six other campus centers across the state,
About Virginia Tech Intellectual Properties, Inc. (VTIP)
Formed in 1985 as an affiliated corporation of
Copyright©2009 PR Newswire.
All rights reserved